Sexual dysfunction: Protocol decreases opioid requirements in IPP patientsJuly 20th 2018
The AUA 2018 sexual dysfunction take-home messages also included a novel end-to-side nerve grafting procedure for men with post-radical-prostatectomy ED as well as the finding that use of a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor does not appear to change the adverse effect profile of flibanserin (Addyi).
AUA ’18: Experts pick this year’s key researchMay 8th 2018
To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.
Shock waves may change future of ED therapyNovember 17th 2017
It’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drugJune 27th 2017
Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
Study: Consumer ads prompt men to seek TRTMay 4th 2017
Findings of an ecologic study indicate that direct-to-consumer advertising for testosterone therapy influenced men to seek treatment and was accompanied by increased testosterone prescribing, including initiation in men without clear indications for use.
Transgender surgery: Videos demonstrate cutting-edge techniques
In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.
Testosterone therapy's big week: One urologist's perspectiveMarch 16th 2017
Abraham Morgentaler, MD, shares why the recent publication of five studies on testosterone therapy in JAMA and JAMA Internal Medicine "was arguably the most important week ever for the science of testosterone therapy and its impact on men's health."
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentJanuary 13th 2017
Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Study offers practical insights on TRT useNovember 1st 2016
Although a recent study of testosterone therapy does not fulfill the need for large-scale, randomized, controlled studies of the treatment, “it is very informative in several ways,” writes Arthur L. Burnett, II, MD, MBA.